SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to a combination of an SEC filing revealing updated change-of-control agreements for senior management, which investors are interpreting as preparation for a potential buyout, and intense short-covering pressure fueled by high borrow fees. The community is actively discussing the stock's positioning ahead of upcoming clinical milestones, with many long-term shareholders expressing conviction in the company's oncology platform while short sellers face significant volatility.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is experiencing intense volatility driven by heavy insider selling, which has fueled widespread community concern about the company's valuation and technical progress. While some bulls remain focused on the potential for government-backed quantum development, many traders are leaning into bearish positions as the stock struggles to maintain support levels amid broader sector de-risking.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense community scrutiny and bearish sentiment as the stock decouples from Bitcoin, leading to heated debates over the sustainability of its debt-fueled acquisition model and dividend obligations. Traders are actively monitoring the stock for a potential bottom while weighing risks of further dilution against claims that it represents a generational buying opportunity.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as it secures critical DOJ clearance for its acquisition of Warner Bros. Discovery, signaling a major milestone for the media conglomerate despite ongoing scrutiny from state attorneys general and international regulators. Community sentiment is heavily focused on the stock's long-term potential following the merger, with many investors debating the impact of integration efforts, regulatory hurdles, and management's strategy to compete with streaming giants.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys is gaining significant momentum as investors track its strategic role in building a domestic U.S. supply chain for critical heavy rare earth elements ahead of upcoming defense procurement mandates. The community is heavily focused on the company's recent partnership agreements, pending financing milestones, and potential index inclusion, viewing the stock as a key long-term play against global supply dependencies.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to a combination of strong fourth-quarter financial results, including an revenue guidance raise to $26 million, and a new partnership with White Castle via Uber Eats. The stock's heavy short interest has fueled significant discussion around the potential for a short squeeze as investors weigh these expansion milestones against ongoing debates about the company's valuation and path to profitability.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio Inc. (IBRX) is trending as investors debate the potential catalyst of a Russell 1000 index inclusion, which could trigger passive institutional buying despite ongoing skepticism regarding the company's eligibility due to banding rules. Meanwhile, the community remains intensely focused on the long-term potential of the Anktiva platform and AI-driven developments, while actively tracking institutional activity and short interest to gauge if a squeeze or significant price breakout is imminent.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as investors weigh significant government loan commitments and a transformational acquisition against recent price volatility and sector-wide weakness. The community remains deeply divided, with bulls pointing to the company's strategic role in securing the domestic uranium and rare earth supply chain, while detractors express frustration over recent price declines and concerns regarding dilution.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors react to positive analyst coverage and a recent operational expansion involving its Pennsylvania manufacturing facility. The community is actively discussing the company's long-term potential within the AI-driven grid infrastructure sector, while weighing the impact of continued share dilution against the momentum from new purchase orders and strategic partnerships.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trending as investors weigh conflicting signals from ongoing geopolitical tensions in the Middle East and the upcoming transition to Fed Chair Kevin Warsh. The community is actively debating the potential for rate hikes, with many traders closely monitoring long-term bond yields and inflation expectations as the primary drivers for price direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters Option to Purchase Additional Shares

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the Company or Definium), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the closing of its previously announced...

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the Company or Definium), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public...

Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals

DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.

DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression

Equity

A single 100-microgram dose of DT120 produced rapid and lasting antidepressant effects that were significantly better than placebo, the company said.

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the Company or Definium), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell...

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

 Definium Therapeutics shares surged as much as 54% on Monday, reaching $37.90 in morning trading as investors reacted positively to developments in the biotech company's research pipeline...

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC, MLTX, FRVO, and SMCI.read more...

Stocks Drift As Chips Extend Gains, Oil Slides On Positive US-Iran Talks

Stocks Drift As Chips Extend Gains, Oil Slides On Positive US-Iran Talks

 Futures are modestly lower coming off the US holiday weekend, after equities finished higher last week with both Dow and Russell clocking new ATHs and SPX finishing in the green for the 11th time in the last 12...

DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results — What Investors Need To Know

Definium said it will host a webcast on Tuesday morning to discuss results from Emerge, a Phase 3 study evaluating DT120 ODT in adults with Major Depressive Disorder.

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in a...

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Extremely Bullish Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Current Price	$44.79
Prev Close	$42.13
Open	$41.99
Dividend Yield	0.00%
50-Day Moving Average	$24.06
Beta	1.70
Avg. Volume	1.6M
PE Ratio	-17.89

52-Week High	$47.01
52-Week Low	$6.40
Market Capitalization	$4.59B
EPS (Annual)	-$2.06
Price to Book	16.71
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DFTXDefinium Therapeutics Inc.

Latest DFTX News